Financial Performance - The company's operating revenue for Q3 2022 was CNY 543,069,898.63, representing a 6.31% increase year-over-year[6]. - The net profit attributable to shareholders for the same period was CNY 42,739,887.75, a decrease of 19.35% compared to the previous year[6]. - The basic earnings per share decreased by 38.30% to CNY 0.29[6]. - Total operating revenue for the period reached ¥1,432,759,189.01, an increase of approximately 5.5% compared to ¥1,357,493,892.62 in the previous period[30]. - Net profit for the period was ¥94,004,084.92, a decrease of approximately 20.5% from ¥118,332,998.14 in the previous period[34]. - The total comprehensive income attributable to the parent company was 94,004,084.92, down from 118,332,735.47 in the previous period[36]. - Basic and diluted earnings per share were both 0.75, compared to 1.05 in the previous period[36]. Assets and Liabilities - Total assets increased by 64.23% to CNY 3,819,466,956.20 compared to the end of the previous year[6]. - The company's total assets increased to ¥3,819,466,956.20, compared to ¥2,325,623,991.84, marking a growth of about 64.3%[29]. - Total liabilities rose to ¥1,678,688,110.30, up from ¥1,377,322,609.70, indicating an increase of approximately 21.8%[29]. - The equity attributable to shareholders of the parent company reached ¥2,140,778,845.90, compared to ¥948,301,382.14, representing a growth of about 126.5%[29]. - The company’s long-term liabilities totaled ¥1,012,057,592.73, up from ¥887,694,447.09, indicating an increase of approximately 14.1%[29]. Cash Flow - Cash flow from operating activities decreased by 6% to CNY 262,784,150.96 due to rising costs[14]. - Cash inflow from operating activities totaled 1,436,491,234.49, an increase from 1,380,931,817.60 in the previous period[37]. - Net cash flow from operating activities was 262,784,150.96, down from 280,012,786.07 in the previous period[40]. - Cash outflow from investing activities was 442,224,509.71, compared to 314,019,922.53 in the previous period[40]. - Net cash flow from financing activities was 1,137,926,181.07, significantly up from 10,500,271.36 in the previous period[40]. - The ending cash and cash equivalents balance was 1,148,370,772.11, compared to 261,806,637.04 in the previous period[40]. - The company reported a net increase in cash and cash equivalents of 977,596,242.79, compared to a decrease of 23,294,176.84 in the previous period[40]. Investments and R&D - R&D expenses increased by CNY 4,360,000, focusing on clinical applications and digital research related to ophthalmology[14]. - Research and development expenses for the period were ¥4,357,149.04, compared to ¥0.00 in the previous period, indicating a new investment in innovation[30]. - The company reported an increase in long-term equity investments to ¥238,570,978.87 from ¥168,881,986.56, reflecting a growth of approximately 41.2%[29]. - The company plans to invest RMB 10,380 million to establish a wholly-owned subsidiary for the new Shenzhen Puri Eye Hospital project[22]. - An additional investment of RMB 7,410.96 million is allocated for the construction of the Hubei Puri Eye Hospital project[22]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,694[14]. - The company completed the election of the third board of directors and the third supervisory board, with new members appointed on October 10, 2022[21]. - The company has not disclosed any related party transactions or concerted actions among shareholders[18]. - The total number of shareholders with priority shares and their holdings was not applicable for this report[19]. - The company has not reported any changes in restricted shares[19]. - The company’s actual controller holds 100% equity in Chengdu Puri Century Investment Co., Ltd.[18]. Current Assets - The company reported a total current asset of RMB 1,148,370,772.11, an increase from RMB 170,774,529.32 in the previous period[23]. - Accounts receivable amounted to RMB 87,054,798.85, up from RMB 54,302,935.42, indicating a growth of approximately 60.3%[23]. - The total current assets amounted to ¥1,524,094,858.92, compared to ¥419,499,744.51, showing a significant increase of about 263.5%[29]. Other Information - The company opened multiple new hospitals, contributing to a 6% increase in sales revenue despite challenges from COVID-19[11]. - Cash and cash equivalents increased significantly, reflecting a strong liquidity position[23]. - The company did not undergo an audit for the third quarter report[41].
普瑞眼科(301239) - 2022 Q3 - 季度财报